Blaine Davis

CIK: 0001802188

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (60.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RNAC

Cartesian Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

RNAC
Cartesian Therapeutics, Inc.
Jan 6, 2026
Sale(S)
Direct
10.6K shares at avg. $6.82$72K
RNAC
Cartesian Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
37K shares-
RNAC
Cartesian Therapeutics, Inc.
Jan 6, 2025
Sale(S)
Direct
4K shares at avg. $16.83$68K
RNAC
Cartesian Therapeutics, Inc.
Jan 3, 2025
Sale(S)
Direct
4K shares at avg. $16.72$66K
RNAC
Cartesian Therapeutics, Inc.
Jan 2, 2025
Award(A)
Direct
22K shares-

		Type	Shares	Price		Ownership
Jan 6, 2026	RNAC Cartesian Therapeutics, Inc.	Sale(S)	10,591	$6.82	$72,227	Direct
Jan 2, 2026	RNAC Cartesian Therapeutics, Inc.	Award(A)	37,000	-	$0	Direct
Jan 6, 2025	RNAC Cartesian Therapeutics, Inc.	Sale(S)	4,028	$16.83	$67,800	Direct
Jan 3, 2025	RNAC Cartesian Therapeutics, Inc.	Sale(S)	3,961	$16.72	$66,235	Direct
Jan 2, 2025	RNAC Cartesian Therapeutics, Inc.	Award(A)	22,000	-	$0	Direct

1-5 of 5 transactions

About Davis Blaine

Davis Blaine (SEC CIK 0001802188) files insider reports with the SEC as Chief Financial Officer of Cartesian Therapeutics, Inc. (RNAC).

Signal8 holds 4 ownership filings by Davis Blaine, all Form 4s, filed between Jan 6, 2025 and Jan 8, 2026. Those filings report 5 transactions, from Jan 2, 2025 to Jan 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Davis Blaine's filings is in FREDERICK, MD.

Recent filings by Davis Blaine

Jan 6, 2026: Open-market sale of RNAC shares (Form 4, code S).
Jan 2, 2026: Grant or award of RNAC shares (Form 4, code A).
Jan 6, 2025: Open-market sale of RNAC shares (Form 4, code S).
Jan 3, 2025: Open-market sale of RNAC shares (Form 4, code S).
Jan 2, 2025: Grant or award of RNAC shares (Form 4, code A).

Other insiders filing for Cartesian Therapeutics, Inc. (RNAC)

Hoge Elizabeth, 10% Owner
Kalayoglu Murat, 10% Owner
Singer Michael, Director
Brunn Carsten, President and CEO
Miljkovic Milos, Chief Medical Officer
DeSilva Nishan M, Director

How to read Form 4 transaction codes